Polar Asset Management Partners’s Summit Therapeutics SMMT Stock Holding History

Polar Asset Management Partners’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-58,400	Closed	-$1.24M	–	792
2025 Q2	$1.24M	Buy	58,400 +45,956	+369%	+$1.05M	0.02%	347
2025 Q1	$240K	Sell	12,444 -14,656	-54%	-$294K	0.01%	363
2024 Q4	$484K	Sell	27,100 -4,200	-13%	-$81.4K	0.01%	475
2024 Q3	$685K	Buy	+31,300	New	+$438K	0.01%	444

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

ACL

APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Polar Asset Management Partners's SMMT Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 58,400 shares — an estimated $1.24M sold.

Polar Asset Management Partners first reported a position in SMMT in Q3 2024 and held it in 4 quarters. The position peaked at $1.24M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

Polar Asset Management Partners reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
Polar Asset Management Partners sold 58,400 Summit Therapeutics shares in Q3 2025, an estimated $1.24M.
Polar Asset Management Partners first reported a position in Summit Therapeutics in Q3 2024 and held it in 4 quarters.
Polar Asset Management Partners's Summit Therapeutics position peaked at $1.24M in Q2 2025.
232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.